# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
After the first six months, eRapa appeared to be safe and well-tolerated with a statistically significant 24% reduction (p=0.04...
Biodexa announced the exercise of previously issued warrants and an agreement between the company and several investors to exer...
Biodexa Announces $7 Million of Gross Proceeds from Warrant ExercisesProceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking...